Oramed Pharmaceuticals (ORMP) Net Income towards Common Stockholders (2011 - 2026)
Oramed Pharmaceuticals (ORMP) posted Net Income towards Common Stockholders of $38.3 million for Q1 2026, up 80.75% on a QoQ basis from $21.2 million in Q4 2025, and up 601.31% year-over-year from $5.5 million in Q1 2025.
Oramed Pharmaceuticals (ORMP) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals' Net Income towards Common Stockholders history runs 15 years deep, the most recent figure standing at $38.3 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 601.31% year-over-year to $38.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.2 million (up 528.42% YoY) and the FY2025 annual result came in at $75.2 million, up 493.67% from the prior year.
- Net Income towards Common Stockholders was $38.3 million for Q1 2026 at Oramed Pharmaceuticals, up from $21.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $48.4 million in Q3 2025 and bottomed at -$19.6 million in Q3 2024.
- A 5-year average of $3.5 million and a median of -$3.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 800.99% — and 2025, when it sank 598.17%.
- Oramed Pharmaceuticals' Net Income towards Common Stockholders stood at -$11.7 million in 2022, then jumped by 213.95% to $13.3 million in 2023, then plunged by 176.71% to -$10.2 million in 2024, then surged by 307.81% to $21.2 million in 2025, then jumped by 80.75% to $38.3 million in 2026.
- Business Quant data shows ORMP's Net Income towards Common Stockholders at $38.3 million in Q1 2026, $21.2 million in Q4 2025, and $48.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | -0.68 |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Oramed Pharmaceuticals | 168.40 Mn | 168.40 Mn | - | 38.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.31 Mn |
| Dec 31, 2025 | 21.20 Mn |
| Sep 30, 2025 | 48.39 Mn |
| Jun 30, 2025 | 13.26 Mn |
| Mar 31, 2025 | -7.64 Mn |
| Dec 31, 2024 | -10.20 Mn |
| Sep 30, 2024 | -19.64 Mn |
| Jun 30, 2024 | 9.20 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 13.30 Mn |
| Sep 30, 2023 | -3.28 Mn |
| Jun 30, 2023 | -1.31 Mn |
| Mar 31, 2023 | -3.40 Mn |
| Dec 31, 2022 | -11.67 Mn |
| Sep 30, 2022 | -7.06 Mn |
| Jun 30, 2022 | -10.53 Mn |
| Mar 31, 2022 | -10.43 Mn |
| Aug 31, 2021 | -22.24 Mn |
| Nov 30, 2019 | -2.45 Mn |
| Aug 31, 2019 | 26.43 Mn |